Literature DB >> 25476259

18F-FDG PET-derived parameters as prognostic indices in hepatic malignancies after 90Y radioembolization: is there a role?

Oreste Bagni1, Luca Filippi, Orazio Schillaci.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25476259     DOI： 10.1007/s00259-014-2966-5

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  21 in total

1.  Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.

Authors:  Shengri Liao; Bill C Penney; Kristen Wroblewski; Hao Zhang; Cassie A Simon; Rony Kampalath; Ming-Chi Shih; Naoko Shimada; Sheng Chen; Ravi Salgia; Daniel E Appelbaum; Kenji Suzuki; Chin-Tu Chen; Yonglin Pu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-09-23       Impact factor: 9.236

2.  PET response criteria for solid tumors predict survival at three months after intra-arterial resin-based 90Yttrium radioembolization therapy for unresectable intrahepatic cholangiocarcinoma.

Authors:  Juan C Camacho; Nima Kokabi; Minzhi Xing; David M Schuster; Hyun S Kim
Journal:  Clin Nucl Med       Date:  2014-11       Impact factor: 7.794

3.  The natural history of primary and secondary malignant tumors of the liver. I. The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy.

Authors:  S Bengmark; L Hafström
Journal:  Cancer       Date:  1969-01       Impact factor: 6.860

4.  Selective internal radiation therapy (SIRT) with 90Yttrium microspheres for extensive colorectal liver metastases.

Authors:  R S Stubbs; R J Cannan; A W Mitchell
Journal:  Hepatogastroenterology       Date:  2001 Mar-Apr

5.  18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer.

Authors:  Alexander R Haug; Beauclair P Tiega Donfack; Christoph Trumm; Christoph J Zech; Marlies Michl; Rüdiger Paul Laubender; Christopher Uebleis; Peter Bartenstein; Volker Heinemann; Marcus Hacker
Journal:  J Nucl Med       Date:  2012-02-13       Impact factor: 10.057

6.  Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI.

Authors:  Ching-yee Oliver Wong; Riad Salem; Subha Raman; Vanessa L Gates; Howard J Dworkin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-03-29       Impact factor: 9.236

Review 7.  From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.

Authors:  Richard L Wahl; Heather Jacene; Yvette Kasamon; Martin A Lodge
Journal:  J Nucl Med       Date:  2009-05       Impact factor: 10.057

8.  Radioembolisation with (90)Y-labelled resin microspheres in the treatment of liver metastasis from breast cancer.

Authors:  R Cianni; G Pelle; E Notarianni; A Saltarelli; P Rabuffi; O Bagni; L Filippi; E Cortesi
Journal:  Eur Radiol       Date:  2012-07-27       Impact factor: 5.315

9.  Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer.

Authors:  Wolfgang Peter Fendler; Donfack Beauclair Philippe Tiega; Harun Ilhan; Philipp M Paprottka; Volker Heinemann; Tobias F Jakobs; Peter Bartenstein; Marcus Hacker; Alexander Robert Haug
Journal:  J Nucl Med       Date:  2013-05-31       Impact factor: 10.057

10.  Transcatheter arterial chemoembolization is a feasible palliative locoregional therapy for breast cancer liver metastases.

Authors:  Sung W Cho; Krit Kitisin; David Buck; Jennifer Steel; Adam Brufsky; Roberta Gillespie; Allan Tsung; James W Marsh; David A Geller; T Clark Gamblin
Journal:  Int J Surg Oncol       Date:  2010-10-28
View more
  1 in total

1.  Molecular response assessed by (68)Ga-DOTANOC and survival after (90)Y microsphere therapy in patients with liver metastases from neuroendocrine tumours.

Authors:  Luca Filippi; Francesco Scopinaro; Giuseppe Pelle; Roberto Cianni; Rita Salvatori; Orazio Schillaci; Oreste Bagni
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-09-02       Impact factor: 9.236
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.